Day One Biopharmaceuticals Hits 52-Week High Amid $2.5 Billion Servier Acquisition Deal

Key Facts

1Day One Biopharmaceuticals (DAWN) stock reached a 52-week high of $21.48.

2Servier is acquiring the company for $2.5 billion, equivalent to $21.50 per share.

3The stock has gained 130% year-to-date and 201.54% over the past year.

4Analysts downgraded the stock to Neutral or Hold as the price approached the acquisition value.

Day One Biopharmaceuticals (DAWN) shares surged to a new 52-week high of $21.48 following the announcement of its acquisition by Servier. The French pharmaceutical giant, Servier, has agreed to acquire the company in an all-cash deal valued at approximately $2.5 billion, or $21.50 per share. This acquisition comes after a period of exceptional performance for DAWN, with the stock gaining over 130% since the beginning of the year and more than 200% over the past 12 months. Despite the positive momentum, several analysts have downgraded the stock to "Neutral" or "Hold" ratings. This shift in sentiment reflects the fact that the current market price is now closely aligned with the agreed buyout price, leaving limited room for further appreciation. The deal underscores the ongoing consolidation within the biotechnology sector as major players seek to expand their portfolios through strategic acquisitions.